bearish
Celltrion's FDA CRL Issue Summary
237 Views09 Apr 2018 05:43
Celltrion Inc (068270 KS) is still right at the center of attention among Korean stock short sellers despite its KOSPI move.What is more critical...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
- Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much30 Aug 2018
- Celltrion (068270): Time Is Not Right for Short Sellers Yet14 Aug 2018
- A Further Study on Celltrion-Celltrion Healthcare Market Cap Spread Movement28 May 2018
- Celltrion's FDA CRL Issue Summary09 Apr 2018
- Celltrion Holdings' ₩200bil CB with Celltrion Healthcare as Pledged Article - Questions to Ask11 Mar 2018
- ION's Celltrion Block Deals - Summary & Impacts07 Mar 2018
- Short Selling Viability Assessment on Celltrion After KOSPI 200 Inclusion03 Mar 2018
x